Data: A certain whale sells TRUMP bought at a high price, giving back profits and losing $900,000 in principal
ChainCatcher reports that, according to EmberCN monitoring, the "whale who missed out on $3.8 million in profits by selling TRUMP before the Trump dinner plan announcement" sold their second high-purchase TRUMP 3 hours ago, giving back profits and losing $900,000 in principal.
In the early hours of April 23, the whale sold 630,000 TRUMP at a price of $8.7, making a profit of $483,000. Afterward, the Trump dinner plan was announced, and the price of TRUMP soared to $16, causing the whale to miss out on $3.8 million in profits;
The whale bought TRUMP at a high price of $15.39 on April 27;
In the early hours of today, the price of TRUMP fell by 13%, and the whale sold their second purchase of TRUMP at a price of $11.29 three hours ago, giving back the first profit of $483,000 and losing $900,000 in principal.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

